Ischemic stroke
Conditions
Interventions
Experimental group:tirofiban hydrochloride sodium chloride injection (tirofiban hydrochloride 5mg and sodium chloride 0.9g), intravenous loading dose of 0.4ug/kg/min for 30min (total dose does not exc
Control group:aspirin 100mg Qd orally/nasogastric tube, and then combined with other anti-thrombotic therapy.
Sponsors
Traditional Chinese and Western Medicine Hospital of Wuhan (Wuhan NO. 1 Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Ages greater than or equal to 18 years old; 2) First onset of acute anterior circulation large vessel occlusive stroke (ICA, MCA-M1/M2) confirmed by CTA/MRA/DSA; 3) Receiving endovascular treatment within 24 hours of stroke onset according to Chinese guidelines; 4) Successful recanalization of culprit artery after endovascular treatment (post-operative eTICI=2C); 5) No-reflow phenomenon is observed in the area of recanalized artery via CTP at 0 hour after neuro-intervention (CBV of the affected side decreased by >15%, compared with the normal side); 6) Patients or their family members provide written informed consent for clinical research.
Exclusion criteria
Exclusion criteria: 1) Pre-stroke mRS=2; 2) Neuro-interventional time window > 24 hours; 3) Intracranial hemorrhage confirmed by imaging before or 0 hour after neuro-intervention; 4) Complicated with serious diseases that might affect the evaluation, such as malignant tumors, severe heart failure or renal failure, etc. 5) Pregnant women; 6) The patient is unable to cooperate with the CTP examination; 7) Allergy to tirofiban, contrast media, anesthetics or other definite contraindications to endovascular therapy; 8) Inherited or acquired bleeding condition, anticoagulant factor deficiency; Or baseline platelet count < 50000/ul; 9) Intracranial aneurysms, arteriovenous malformations, brain tumors with space-occupying effect on imaging; 10) Suspected bacterial embolism or bacterial endocarditis; 11) Any history of bleeding (gastrointestinal and urinary tract bleeding) in the past one month; 12) Severe organic diseases with life expectancy < 90 days; 13) Are not expected to complete follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRS at 90 days after EVT; | — |
Secondary
| Measure | Time frame |
|---|---|
| mRS 0-1 (%) at 90 days;mRS 0-2 (%) at 90 days;90-day mRS improvement (shift analysis);Change in stroke severity (NIHSS score) at 24 hours after EVT;Change in stroke severity (NIHSS score) at 7 days after EVT or at discharge, whichever occurred first;NIHSS score and change at 90 days;EQ-5D scale score at 90 days; | — |
Countries
China
Contacts
Public ContactGuohua Chen
Traditional Chinese and Western Medicine Hospital of Wuhan (Wuhan NO. 1 Hospital)
Outcome results
None listed